公开(公告)号：US20200155497A1

公开(公告)日：2020-05-21

申请号：US16743411

申请日：2020-01-15

Applicant: Sanofi Mature IP

Inventor： Sunil GUPTA

IPC: A61K31/337 ,  A61K31/164 ,  A61K31/56 ,  A61K31/573 ,  A61K45/06 ,  A61K38/19

Abstract: The invention relates to a compound of formula: which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.

公开(公告)号：US20210244704A1

公开(公告)日：2021-08-12

申请号：US17031301

申请日：2020-09-24

Applicant: SANOFI MATURE IP

Inventor： Samira BENSFIA

IPC: A61K31/337 ,  A61K31/4166 ,  A61K31/58 ,  A61K31/573 ,  A61K38/19 ,  A61P35/00

Abstract: Provided herein are methods of using cabazitaxel in mCRPC patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent.

公开(公告)号：US10716777B2

公开(公告)日：2020-07-21

申请号：US16743411

申请日：2020-01-15

Applicant: Sanofi Mature IP

Inventor： Sunil Gupta

IPC: A61K31/337 ,  A61K31/164 ,  A61K31/56 ,  A61K31/573 ,  A61K45/06 ,  A61K38/19

Abstract: The invention relates to a compound of formula: which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.

公开(公告)号：US20240139146A1

公开(公告)日：2024-05-02

申请号：US18224122

申请日：2023-07-20

Applicant: Sanofi Mature IP

Inventor： Sunil GUPTA

IPC: A61K31/337 ,  A61K31/164 ,  A61K31/56 ,  A61K31/573 ,  A61K38/19 ,  A61K45/06

CPC classification number: A61K31/337 ,  A61K31/164 ,  A61K31/56 ,  A61K31/573 ,  A61K38/193 ,  A61K45/06

Abstract: The invention relates to a compound of formula:




which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.

公开(公告)号：US20210169843A1

公开(公告)日：2021-06-10

申请号：US16931802

申请日：2020-07-17

Applicant: Sanofi Mature IP

Inventor： Sunil GUPTA

IPC: A61K31/337 ,  A61K45/06 ,  A61K31/164 ,  A61K31/573 ,  A61K38/19 ,  A61K31/56

Abstract: The invention relates to a compound of formula: which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.